

## Diversification Update at 31/05/2012

TOBAM's Diversification Ratio (DR) <sup>1</sup> measures to what extent a portfolio is diversified. The DR <sup>2</sup> (square of the diversification ratio) corresponds to the number of independent degrees of freedom in a particular portfolio – or the number of independent variables at work. As the table shows, the “broad market” indices leave diversification on the table. In addition to a snapshot of each market's DR <sup>2</sup> , the table shows the DR <sup>2</sup> of a well-diversified portfolio, and the fraction of available diversification used by the index.	<i>DR<sup>2</sup> - Index diversification</i>		<i>DR<sup>2</sup> - Maximum diversification</i>	<i>% diversification used by index</i>
	<b>MSCI EMU</b>	1.66	3.61	46%
	<b>MSCI US</b>	1.74	3.76	46%
	<b>MSCI UK</b>	1.77	2.79	63%
	<b>MSCI Japan</b>	2.43	7.67	32%
	<b>MSCI World</b>	2.25	4.97	45%
	<b>MSCI Australia</b>	1.69	2.89	58%
	<b>MSCI Emerging<sup>2</sup></b>	2.96	4.37	68%

## An apple a day, not the whole orchard

### *Apple's weight in the benchmark*

Apple's stock price volatility could cause some indigestion for investors with significant exposure to the stock by virtue of their active or passive positions managed against the US equity indices of which Apple is a member.

For the benchmark, Apple's weight is sizeable – 20% in the NASDAQ and 4% in the MSCI USA as of May 31, 2012. In terms of benchmark risk, Apple is also responsible for about 5% of index volatility – for an index with 600 members and about 12% volatility year to date through May. Indeed, the IT sector, dominated by Apple, is the largest contributor to benchmark risk for the year and year to date periods ended May 31, 2012, surpassing even that of Financials. This is not a surprising phenomenon, given that the benchmark's strategy consists of increasing its position in line with increasing market capitalization.

For the Anti-Benchmark, Apple is no longer as diversifying as the other stocks selected from the MSCI USA index. Apple accounts for a disproportionate share of risk in the market, all the while being more correlated with the market and with the AB US portfolio than the rest of the portfolio. As such, Apple is not held in the AB US portfolio.

TOBAM's objective, to maximize diversification, translates to holding the most complementary, or least correlated, mix of stocks possible in a given investment universe, to ensure that no single risk factor dominates overall portfolio risk. The table below illustrates this rationale: Apple is indeed *less correlated* to the AB portfolio than the average MSCI stock, but Apple is still *more correlated to the AB US portfolio* than all other stocks held in the portfolio:

	<b>Average AB US stocks</b>	<b>Apple</b>	<b>Average MSCI US stocks</b>
<b>Ex-ante correlation with AB US</b>	53.9%	61.1%	70.4%
<b>Ex-ante correlation with MSCI US</b>	51.7%	65.4%	73.9%


<sup>1</sup>TOBAM's Diversification Ratio measures a portfolio's or index's diversification. It is supported by original research and is based on a mathematical definition of diversification. TOBAM's “Anti-Benchmark” Most Diversified Portfolio<sup>®</sup> maximizes this Diversification Ratio. Maximizing diversification within a universe of securities provides a result closer to the true market risk premium from that universe. “Maximum Diversification<sup>®</sup>” and “MaxDiv<sup>®</sup>” are registered trademarks of TOBAM.

<sup>2</sup> The Anti-Benchmark Emerging Markets Equity strategy filters the reference index to the 200 largest market capitalizations.

Indeed, as set out in TOBAM's working article "[Properties of the Most Diversified Portfolio](#)," any stock *not held* by the MDP is necessarily *more* correlated to the MDP than any stock belonging to it. This brings us to an equally important point: without needing to hold Apple, the AB US portfolio is nonetheless exposed to the Apple risk factor. Adding Apple to the AB portfolio would in fact decrease diversification.

Finally, the rise in Apple's stock price corresponds to a period of declining diversification for the MSCI USA universe. Comparing Diversification Ratios *squared* (DR2s) for the benchmark and the portfolio reveals that the available diversification for the market has decreased over the past year, and concentration has increased, as observed in the benchmark's ever-increasing allocation to Apple, as well as to IT and Technology stocks:

### Diversification Ratios squared vs. Apple stock price Year ended May 31, 2012



Once this concentration begins to reverse course, we expect the resulting increase in available diversification to be favorable for Anti-Benchmark strategies, which do not target a specific characteristic, such as attractive valuations, low volatility, or low tracking error, but rather the mix of stocks that maximizes the portfolio's Diversification Ratio, which in turn aims to deliver competitive performance and lower volatility.

## For more information

TOBAM is an asset management company offering innovative investment capabilities whose aim is to maximize diversification. TOBAM's flagship Anti-Benchmark® strategies, supported by original research and a mathematical definition of diversification, provide clients with diversified core equity exposure, both globally and in domestic markets. FTSE also publishes the FTSE TOBAM Maximum Diversification Index Series based on the Anti-Benchmark equity portfolio construction methodology. The company manages over \$2.3 billion via its Anti-Benchmark strategies for institutional clients worldwide. Its team includes sixteen financial professionals based in Paris, Los Angeles and Amsterdam (31.03.2012).

## Contacts:

### Head of Business Development

Christophe Roehri  
+33 1 53 23 41 60  
[Christophe.Roehri@tobam.fr](mailto:Christophe.Roehri@tobam.fr)

### TOBAM North America

Steve Sapra, Ph.D., CFA  
+1 646 240 4660  
[Steve.Sapra@tobam.fr](mailto:Steve.Sapra@tobam.fr)

### Benelux

Morella Hessels  
+31 203 012 106  
[Morella.Hessels@tobam.fr](mailto:Morella.Hessels@tobam.fr)

### United Kingdom

Laura Vu Thien  
+33 1 53 23 41 65  
[Laura.VuThien@tobam.fr](mailto:Laura.VuThien@tobam.fr)

### Client Service

Elizabeth Breaden  
Tel. +33 1 53 23 41 56  
[ClientService@tobam.fr](mailto:ClientService@tobam.fr)

### TOBAM Marketing Partners

#### Nordics - Paxstone Capital LLP

Kasper Kemp Hansen  
Tel. +45 36 95 97 00  
[kasper.hansen@paxstone.com](mailto:kasper.hansen@paxstone.com)

#### Canada - Investeam

Nancy Nightingale  
Tel. +1 416 860 9490  
[nancy.nightingale@investeam.ca](mailto:nancy.nightingale@investeam.ca)

#### Australia & NZ - Phoenix Capital Advisory Ltd.

Mark Jackson [mark.jackson@phoenixcap.com.au](mailto:mark.jackson@phoenixcap.com.au)  
Matthew Wormald [matt.wormald@phoenixcap.com.au](mailto:matt.wormald@phoenixcap.com.au)  
Tel. +612 9947 9781

## Disclaimers

*This document is intended for professional investors only. This document is confidential and may not be reproduced in any form without the express permission of TOBAM and to the extent that it is passed on, care must be taken to ensure that any reproduction is in a form which accurately reflects the information presented here. While TOBAM believes that the information is correct at the date of production, no warranty or representation is given to this effect and no responsibility can be accepted by TOBAM to the recipient of this document or end users for any action taken on the basis of the information contained herein. We do not represent that this information, including any third party information, is accurate or complete and it should not be relied upon as such. No reliance may be placed for any purpose on the information and opinions contained in this document or their accuracy or completeness. Opinions expressed herein reflect the opinion of TOBAM and are subject to change without notice. This document is for information purposes and does not constitute advice or a recommendation to enter into any transaction or an offer or an agreement, or a solicitation of an offer or an agreement, to enter into any transaction, nor shall it or the fact of its distribution form the basis of, or be relied on in connection with, any contract for the same. The fund(s) that may be mentioned in this email or document may not be eligible for sale in some states or countries and they may not be suitable for all types of investors. Before entering into any transaction, you should consider the suitability of the transaction to your particular circumstances and independently review (with your professional advisers as necessary) the specific financial risks as well as the legal, regulatory, credit, tax and accounting consequences of entering into such transaction. The value and the income produced by a strategy may be adversely affected by exchange rates, interest rates, or other factors so that an investor may get back less than he or she invested. Past performance is not indicative of future results.*

**Copyrights:** All text, graphics, interfaces, logos and artwork, including but not limited to the design, structure, selection, coordination, expression, "look and feel" and arrangement contained in this presentation, are owned by TOBAM and are protected by copyright and various other intellectual property rights and unfair competition laws.

**Trademarks:** "TOBAM," "MaxDiv," "Maximum Diversification," "Diversification Ratio," "Most Diversified Portfolio," "Most Diversified Portfolios," "MDP" and "Anti-Benchmark" are registered trademarks. The absence of a product or service name from this list does not constitute a waiver of TOBAM trademark or other intellectual property rights concerning that name.

**Patents:** The Anti-Benchmark, MaxDiv and Maximum Diversification strategies, methods and systems for selecting and managing a portfolio of securities, processes and products are patented or patent pending.

**Knowledge, processes and strategies:** The Anti-Benchmark, MaxDiv and Maximum Diversification strategies, methods and systems for selecting and managing a portfolio of securities, processes and products are protected under unfair competition, passing-off and misappropriation laws.

**Terms of use:** TOBAM owns all rights to, title to and interest in TOBAM products and services, marketing and promotional materials, trademarks and Patents, including without limitation all associated Intellectual Property Rights. Any use of the intellectual property, knowledge, processes and strategies of TOBAM for any purpose and under any form (known and/or unknown) in direct or indirect relation with financial products including but not limited to certificates, indices, notes, bonds, OTC options, warrants, mutual funds, ETFs and insurance policies (i) is strictly prohibited without TOBAM's prior written consent and (ii) requires a license.

This document is issued by TOBAM which is authorized and regulated by the Autorité des Marchés Financiers ("AMF").